Retatrutide: What Makes a Triple Agonist Different From Semaglutide and Tirzepatide

For Research Use Only. Not approved for human use or consumption. Intended strictly for in vitro laboratory research.

Semaglutide and tirzepatide have dominated the metabolic research conversation for the past several years. Retatrutide adds a third receptor target — glucagon — to the combination. That addition changes the mechanism in ways that are drawing significant research attention.

A Quick Map of the Receptor Landscape

To understand why retatrutide is different, it helps to understand what each receptor does in metabolic regulation:

• GLP-1R (Glucagon-Like Peptide-1 Receptor) — Stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, reduces appetite via central signaling. Targeted by semaglutide, tirzepatide, and retatrutide.
• GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor) — Also stimulates insulin secretion in a glucose-dependent manner, with additional effects on fat storage and energy regulation. Targeted by tirzepatide and retatrutide; not targeted by semaglutide.
• GcgR (Glucagon Receptor) — Classically associated with hepatic glucose production and counter-regulation of insulin. At pharmacological doses, glucagon receptor agonism also increases energy expenditure and promotes fat oxidation. Targeted only by retatrutide among approved or late-stage investigational compounds.

Semaglutide: Single-Target GLP-1 Agonism

Semaglutide (active compound in Ozempic and Wegovy) is a GLP-1 receptor agonist. It drives weight reduction primarily through appetite suppression and slowed gastric emptying. Phase 3 data showed approximately 15–17% body weight reduction over 68 weeks in the STEP trial. Its mechanism is well-characterized and its safety profile is the most established of the three compounds.

Tirzepatide: Dual GLP-1/GIP Agonism

Tirzepatide (Mounjaro, Zepbound) targets both GLP-1R and GIPR. The addition of GIP agonism appears to enhance the weight loss effect beyond what GLP-1 alone produces — the SURMOUNT-1 trial showed approximately 22% body weight reduction at the highest dose over 72 weeks. The exact mechanism of the additive effect is still being studied; GIP may work synergistically with GLP-1 on both peripheral tissue and central appetite regulation.

Retatrutide: Triple GLP-1/GIP/Glucagon Agonism

Retatrutide (LY3437943) adds glucagon receptor agonism to the GLP-1/GIP combination. The phase 2 trial published in the New England Journal of Medicine (2023) reported up to 24.2% body weight reduction at 48 weeks — the highest reported in any large-scale obesity drug trial at the time of publication.

The glucagon receptor component is the mechanistic differentiator. While glucagon is typically thought of as a counter-regulatory hormone that raises blood glucose, glucagon receptor agonism at calibrated doses has a different effect in the context of triple agonism:

• Increases hepatic fat oxidation and reduces liver fat
• Elevates basal metabolic rate through thermogenic effects
• May reduce lipid accumulation in the liver (hepatic steatosis)

Retatrutide is currently in Phase 3 clinical development.

Key Mechanistic Differences at a Glance

Why This Matters for Metabolic Research

The progression from mono- to dual- to triple-agonism represents a research trajectory, not just incremental dose increases. Each receptor addition introduces a new mechanism that interacts with the others. Understanding how GLP-1, GIP, and glucagon receptor co-stimulation affects insulin sensitivity, hepatic lipid metabolism, and energy expenditure at the cellular and systems level is an active area of inquiry.

For more on the clinical data comparing retatrutide and semaglutide directly, see our Retatrutide vs Semaglutide: What the Clinical Trial Data Shows. For researchers sourcing retatrutide, our sourcing guide covers what to look for in vendor documentation.

View Retatrutide →